22 Dec 2017 07:00
AMPHION INNOVATIONS PLC
("Amphion" or "the Company")
Extended Repayment and Additional Draw Down on Loan Facility
London and New York, Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that the Company has agreed terms for re-structuring the loan payments under the Facility and the draw-down of an additional US $1,550,000 (an "Additional Draw") under the loan facility as announced on 5 June 2014 (the "Facility").
The loan balance under the Facility after the Additional Draw will be US $6,187,786 including fees and accrued interest through the date of close. The loan balance will be repaid in 7 monthly instalments from 15 June - 15 December 2018. Prior to this change the loan balance would have come due on 15 January 2018.
Under the terms of the Additional Draw, the interest rate will be 10%. The Lender will also receive 10% of the appreciation on 12,000,000 ordinary shares of Motif Bio plc above 35 pence. The proceeds are to be used for working capital for Amphion and its Partner Companies.
The current loan under the Facility continues to be secured by the pledge by the Company of 36,371,625 ordinary shares of Motif Bio plc. Amphion has transferred the legal title to, but retains the beneficial interest in, the total pledged shares. The Lender has agreed not to sell any ordinary shares of Motif Bio plc until 15 June 2018 as long as the Company remains in compliance with the terms of the Facility.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information please contact:
Amphion Innovations | Tel: +1 (212) 210 6224 | ||||
Charlie Morgan | |||||
Panmure Gordon Limited (Nominated Adviser and Corporate Broker) | Tel: +44 (0)20 7886 2500 | ||||
Freddy Crossley / Ryan McCarthy (Corporate Finance) | |||||
Charlie Leigh-Pemberton (Corporate Broking) | |||||
Northland Capital Partners Limited (Joint Corporate Broker) | Tel: +44 (0)20 3861 6625 | ||||
Patrick Claridge / David Hignell (Corporate Finance) | |||||
John Howes (Corporate Broking) | |||||
Walbrook PR | Tel: +44 (0)20 7933 8780 or | ||||
Mike Wort/ Paul McManus | amphion@walbrookpr.com | ||||
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.
On the web: www.amphionplc.com